<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="452">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155267</url>
  </required_header>
  <id_info>
    <org_study_id>1-1</org_study_id>
    <nct_id>NCT05155267</nct_id>
  </id_info>
  <brief_title>Micro and Nanoplastics as a Biomarker of Exposure and Effect in Chronic Kidney Disease Patients</brief_title>
  <official_title>Micro and Nanoplastics as a Biomarker of Exposure and Effect in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ricard Marcos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital universitario Virgen de Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitat Autonoma de Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Micro and nanoplastics (MNPLs) effects on human heath is still preliminary. Chronic kidney&#xD;
      disease (CKD) participants, specially does patients submitted to hemodialysis, is a&#xD;
      population high exposed to plastics. The objective of our research is to be able to detect&#xD;
      MNPLs on biological fluids of hemodialysis patients as well as their potential genotoxic and&#xD;
      inmunological damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The exponential increase in the production/use of plastic translates into a parallel increase&#xD;
      of environmental plastic- waste that is continuously degraded into micro and nanoplastics&#xD;
      (MNPLs). Information on the MNPLs' effects on human health is still preliminary and,&#xD;
      furthermore, the limitations in current methodologies prevent accurate human exposure/risk&#xD;
      assessment.&#xD;
&#xD;
      This observational study will obtain biological samples of hemodialysis Chronic Kidney&#xD;
      disease (CKD) patients as a reference and vulnerable group of individuals high exposed to&#xD;
      MNPLs and potentially more susceptible. This will allow the optimization of specific&#xD;
      biomarkers of human MNPLs exposure and the characterization of biomarkers of early effect&#xD;
      that allows an association among the exposure to MNPLs and effects on human health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Biomonitoring study to detect the presence of MNPLs in biological fluids</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Micro and nanoplastic and/or derivatives, would be evaluated. Characterization of possible biomarkers of early biological effects on human health</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study of the effects of MNPLs on imme system</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Impact evaluation of MNPLs on transcriptome, secretome and inflammatory signalling and inflamasome activation. Investigating the effect of MNPLs on the function of the immune system in vivo and in high-risk individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotoxicity effects of exposure to MNPLs</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Genotoxic, chromosome damage evaluation and oxidative DNA damage will be analysed by the Comet assay and the micronucleus assay</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Microplastics</condition>
  <condition>Nanoplastics</condition>
  <condition>Genotoxic Damage</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney disease participants (CKD)</arm_group_label>
    <description>CKD submitted to hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomonitoring study to detect MNPLs in biological samples and study of their health effects</intervention_name>
    <description>Determination of MNPLs levels, genotoxic damage and inmunological effects</description>
    <arm_group_label>Chronic Kidney disease participants (CKD)</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This project will study a minimum of 25 adult participants with chronic kidney disease,&#xD;
        included in an haemodialysis programme. A control group (matched by gender, age and&#xD;
        lifestyle with CKD participants) will be also included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Chronic Kidney Disease (CKD):&#xD;
&#xD;
          -  Participant submitted to hemodialysis for more than 3 months&#xD;
&#xD;
          -  Between 18 and 70 yeard old&#xD;
&#xD;
          -  Stable haemoglobin (more than 10 gr/dl)&#xD;
&#xD;
          -  Absence of infectious disease at the date of sample collection and for a period of&#xD;
             more than two weeks&#xD;
&#xD;
          -  Absence of active neoplasia&#xD;
&#xD;
          -  Stable vascular access&#xD;
&#xD;
        Inclusion Criteria for controls :&#xD;
&#xD;
          -  Between 18 and 70 yeard old&#xD;
&#xD;
          -  Absence of chronic kidney disease or dialysis treatment&#xD;
&#xD;
          -  Absence of chronic pathology (including neoplasia)&#xD;
&#xD;
          -  Absence of infectious disease at the date of sample collection and for a period of&#xD;
             more than two weeks&#xD;
&#xD;
          -  Spanich residence&#xD;
&#xD;
        Exclusion Criteria for CKD:&#xD;
&#xD;
          -  Clinical instability&#xD;
&#xD;
          -  Life expectancy of more than 12 months&#xD;
&#xD;
          -  Coagulation system disorders&#xD;
&#xD;
          -  Participation in other clinical study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unsigned informed consent&#xD;
&#xD;
        Exclusion criteria for controls:&#xD;
&#xD;
          -  Participation in other clinical study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unsigned informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Pelegrín</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Murciano de Investigación Biosanitaria (IMIB)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Bernardo Cabezuelo</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario Virgen Arrixaca (Murcia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Martínez</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario Virgen Arrixaca (Murcia)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricard Marcos</last_name>
    <phone>+34 93 586 20 52</phone>
    <email>ricard.marcos@uab.cat</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitat Autonoma de Barcelona</investigator_affiliation>
    <investigator_full_name>Ricard Marcos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>MNPLs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

